查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1603799

2030 年前列腺素琴酒市场预测：按产品类型、给药途径、分销管道、应用和地区进行的全球分析

Prostaglandin Analogs Market Forecasts to 2030 - Global Analysis By Product Type, Route of Administration, Distribution Channel, Application and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2024 年全球琴酒类似物市场规模为 39 亿美元，预计到 2030 年将达到 61 亿美元，预测期内复合年增长率为 7.5%。

称为前列腺素琴酒的合成物质复製了天然琴酒的作用，天然前列腺素是参与许多生理功能（例如发炎和平滑肌收缩）的脂质分子。这些类似物常用于眼科治疗，特别是用于降低青光眼等疾病的眼内压。

根据《药理学前沿》发表的一项临床研究，琴酒类似物 (PGA) 被认为是治疗青光眼的一线药物，最有效的长期治疗是 0.03% 比Bimatoprost，其次是0.005% 比马前列素。

眼科疾病盛行率上升

青光眼、高眼压症和其他眼科疾病的盛行率不断增加，推动了对琴酒类似物的需求。随着世界人口老化，这些疾病的盛行率不断增加，需要有效的治疗方法。前列腺素琴酒能有效降低眼压，使其成为许多眼科疾病的第一线药物。疾病负担的增加导致寻求治疗的患者增加，从而推动了市场的成长。

高成本

名牌前列腺素琴酒的高成本可能会限制病患的使用和市场成长，特别是在新兴市场。专利保护使製造商能够为这些药物争取高价。研究开发、临床试验和监管核准成本均反映在最终产品成本中。对许多患者来说，长期使用这些药物会带来巨大的经济负担。这种成本障碍可能会导致一些患者选择更便宜的替代治疗。

扩展到新的治疗领域

前列腺素琴酒不仅可用于青光眼和高眼压症，还可用于其他治疗领域。正在进行的研究正在调查其对干眼、视网膜疾病和角膜癒合等疾病的有效性。这些药物的发炎和神经保护特性使其成为各种眼科应用的有希望的候选药物。如果新适应症开拓成功，市场将显着扩大，并为製造商提供新的收入来源。

监管挑战

眼科药物严格的监管要求对市场成长构成威胁。获得并维持前列腺素琴酒的核准既耗时又昂贵。监管变化、安全问题或不利事件可能导致市场退出或限制。上市后监测和药物安全检测要求增加了营运成本。对于这个市场上的製造商来说，应对不同地区复杂的监管环境是一个持续的挑战。

COVID-19 的影响：

COVID-19 大流行以多种方式扰乱了琴酒类似物市场。封锁和安全措施减少了患者定期看眼科医生的次数，可能会延迟诊断和治疗的开始。供应链中断影响了製造和分销。然而，这种流行病也可能加速远端医疗在眼科照护中的采用，改善长期获得处方和后续观察的机会。随着医疗保健系统的復苏，对眼保健服务的需求不断增长可能会推动市场成长。

预计在预测期内外用药物领域将是最大的

预计外用药物领域将在预测期内获得最大的市场占有率。局部给药（主要透过眼药水）是琴酒类似物的主要给药途径。这种方法有几个优点，包括直接给药到目标部位、最小的全身吸收以及患者易于使用。局部製剂可以实现精确的剂量，并且比全身性治疗的副作用更少。许多琴酒类似物眼药水每天一次的便利性提高了患者的依从性。局部给药系统的持续创新，例如无防腐剂配方和缓释性技术，进一步支持了该领域的成长。

预计高眼压领域在预测期内的复合年增长率最高。

预计高眼压细分市场在预测期内将显着成长。高眼压的特征是眼压升高，但没有视神经损伤或视野缺陷，代表着巨大的市场机会。琴酒类似物的早期疗育可以有效控制眼压并防止进展为青光眼。高眼压已被认为是青光眼的危险因素，筛检和开始治疗的强度正在增加。随着诊断技术的进步，更多的病例可以更早被发现。控制高眼压的预防性方法预计将推动这一领域的快速成长。

比最大的地区

预计北美地区在预测期内将占据最大的市场占有率。该地区青光眼和高眼压症发病率很高，而且人口老化。先进的医疗基础设施和高额医疗支出扩大了这些药物的取得范围。主要市场参与者的强大影响力和持续的研究活动有助于保持市场领先地位。此外，优惠的青光眼治疗报销政策和保险范围正在支持市场成长。

复合年增长率最高的地区：

预计亚太地区在预测期内将实现最高的复合年增长率。因素包括人口众多且老化、眼科疾病率增加、医疗保健的普及。在中国和印度等国家，可支配收入的增加和中阶的壮大使得先进的治疗方法变得更便宜。政府为防治失明和改善眼部保健所做的努力正在创造有利的市场环境。人们对眼睛健康意识的提高和医疗保健基础设施的扩大也有助于该地区的市场扩张。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场公司的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争标基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 研究资讯来源
    • 主要研究资讯来源
    • 二次研究资讯来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 应用分析
  • 新兴市场
  • COVID-19 的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球琴酒类似物市场：依产品类型

  • 拉坦前列素
  • Bimatoprost
  • 曲伏前列素
  • 他氟前列素
  • 其他产品类型

第六章全球琴酒类似物市场：依给药途径

  • 外用
  • 口服
  • 注射

第七章全球琴酒类似物市场：按分销管道

  • 医院药房
  • 零售药房
  • 专业药房
  • 线上交付

第八章全球琴酒类似物市场：按应用

  • 青光眼治疗
  • 促进睫毛生长
  • 眼压升高
  • 干眼症
  • 保护胃
  • 其他应用

第九章全球琴酒类似物市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第10章 主要进展

  • 合约、伙伴关係、合作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务拓展
  • 其他关键策略

第十一章 公司概况

  • Pfizer Inc.
  • Allergan plc
  • Novartis AG
  • Bayer AG
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Santen Pharmaceutical Co., Ltd.
  • Ocular Therapeutix, Inc.
  • Aerie Pharmaceuticals, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Yonsung Fine Chemicals
  • Everlight Chemical
  • Piramal Enterprises
  • Bio-Techne Corporation
  • Mironova Labs
  • Chirogate
  • Cepia, LLC
  • Johnson Matthey
Product Code: SMRC27821

According to Stratistics MRC, the Global Prostaglandin Analogs Market is accounted for $3.9 billion in 2024 and is expected to reach $6.1 billion by 2030, growing at a CAGR of 7.5% during the forecast period. Synthetic substances called prostaglandin analogs replicate the actions of natural prostaglandins, which are lipid molecules involved in a number of physiological functions like inflammation and smooth muscle contraction. To reduce intraocular pressure in diseases like glaucoma, these analogs are frequently used in medical treatments, particularly in ophthalmology.

According to clinical research published in Frontiers in Pharmacology, prostaglandin analogs (PGAs) are considered the first-line treatment for glaucoma, with the most effective long-term therapy being 0.03% bimatoprost, followed by 0.005% latanoprost and 0.004% travoprost.

Market Dynamics:

Driver:

Rising prevalence of ophthalmic conditions

The increasing incidence of glaucoma, ocular hypertension, and other eye disorders is driving demand for prostaglandin analogs. As the global population ages, the prevalence of these conditions is growing, necessitating effective treatments. Prostaglandin analogs have become a first-line therapy for many ophthalmic issues due to their efficacy in lowering intraocular pressure. The rising disease burden is compelling more patients to seek treatment, fueling market growth.

Restraint:

High costs

The high costs associated with branded prostaglandin analog medications can limit patient access and market growth, especially in developing regions. Patent protection allows manufacturers to charge premium prices for these drugs. The expenses of research, development, clinical trials, and regulatory approvals are reflected in the final product costs. For many patients, the long-term use of these medications represents a significant financial burden. This cost barrier may lead some to opt for alternative, less expensive treatments.

Opportunity:

Expansion into new therapeutic areas

There is potential to expand the use of prostaglandin analogs beyond glaucoma and ocular hypertension into other therapeutic areas. Ongoing research is exploring their efficacy for conditions like dry eye disease, retinal disorders, and corneal healing. The anti-inflammatory and neuroprotective properties of these drugs make them promising candidates for various ophthalmic applications. Successful development of new indications would significantly expand the market and provide additional revenue streams for manufacturers.

Threat:

Regulatory challenges

Stringent regulatory requirements for ophthalmic medications pose a threat to market growth. Obtaining and maintaining regulatory approvals for prostaglandin analogs can be a lengthy and costly process. Changing regulations, safety concerns, or adverse events could lead to market withdrawals or restrictions. Post-marketing surveillance and pharmacovigilance requirements add to operational costs. Navigating the complex regulatory landscape across different regions presents ongoing challenges for manufacturers in this market.

Covid-19 Impact:

The COVID-19 pandemic disrupted the prostaglandin analogs market in several ways. Lockdowns and safety measures led to reduced patient visits for routine eye care, potentially delaying diagnoses and treatment initiations. Supply chain disruptions affected manufacturing and distribution. However, the pandemic also accelerated the adoption of telemedicine for ophthalmic care, potentially improving long-term access to prescriptions and follow-ups. As healthcare systems recover, pent-up demand for eye care services may drive market growth.

The topical segment is expected to be the largest during the forecast period

The topical segment is predicted to secure the largest market share throughout the forecast period. Topical administration, primarily through eye drops, is the dominant route for prostaglandin analogs. This method offers several advantages, including direct delivery to the target site, minimal systemic absorption, and ease of use for patients. Topical formulations allow for precise dosing and reduced side effects compared to systemic treatments. The convenience of once-daily application for many prostaglandin analog eye drops improves patient compliance. Ongoing innovations in topical drug delivery systems, such as preservative-free formulations and sustained-release technologies, are further driving the growth of this segment.

The ocular hypertension segment is expected to have the highest CAGR during the forecast period

The ocular hypertension segment is projected to witness substantial growth during the projection period. Ocular hypertension, characterized by elevated intraocular pressure without optic nerve damage or visual field loss, represents a significant market opportunity. Early intervention with prostaglandin analogs can effectively manage intraocular pressure and potentially prevent progression to glaucoma. The growing awareness of ocular hypertension as a risk factor for glaucoma is leading to increased screening and treatment initiation. As diagnostic technologies improve, more cases are being identified at earlier stages. The preventive approach to managing ocular hypertension is expected to drive rapid growth in this segment.

Region with largest share:

The North America region is projected to account for the largest market share during the forecast period. The region has a high prevalence of glaucoma and ocular hypertension, coupled with an aging population. Advanced healthcare infrastructure and high healthcare spending enable greater access to these medications. Strong presence of key market players and ongoing research activities contribute to market leadership. Additionally, favorable reimbursement policies and insurance coverage for glaucoma treatments support market growth.

Region with highest CAGR:

The Asia Pacific region is projected to achieve the highest CAGR during the forecast period. Factors driving this include a large and aging population, increasing prevalence of eye disorders, and improving healthcare access. Rising disposable incomes and an expanding middle class in countries like China and India are enabling greater affordability of advanced treatments. Government initiatives to combat blindness and improve eye care are creating a favorable market environment. Growing awareness of eye health and expanding healthcare infrastructure are also contributing to market expansion in this region.

Key players in the market

Some of the key players in Prostaglandin Analogs Market include Pfizer Inc., Allergan plc, Novartis AG, Bayer AG, GlaxoSmithKline plc, Merck & Co., Inc., Santen Pharmaceutical Co., Ltd., Ocular Therapeutix, Inc., Aerie Pharmaceuticals, Inc., Sun Pharmaceutical Industries Ltd., Yonsung Fine Chemicals, Everlight Chemical, Piramal Enterprises, Bio-Techne Corporation, Mironova Labs, Chirogate, Cepia, LLC, and Johnson Matthey.

Key Developments:

In October 2024, GSK plc and Chimagen Biosciences (Chimagen), a privately held biotechnology company, announced an agreement for GSK to acquire CMG1A46, a clinical-stage dual CD19 and CD20-targeted T cell-engager (TCE), from Chimagen for $300 million upfront. GSK plans to develop and commercialise CMG1A46 with a focus on B cell-driven autoimmune diseases, such as systemic lupus erythematosus (SLE) and lupus nephritis (LN), with potential to expand into related autoimmune diseases.

In September 2024, Novartis announced that the US Food and Drug Administration (FDA) has approved Kisqali(R) (ribociclib) in combination with an aromatase inhibitor (AI) for the adjuvant treatment of people with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) stage II and III early breast cancer (EBC) at high risk of recurrence, including those with node-negative (N0) disease.

In November 2023, Santen received European Commission approval for Catiolanze(R), a cationic emulsion of latanoprost 50μg/mL. This preservative-free prostaglandin analog is indicated for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The approval follows positive results from a Phase III clinical trial that demonstrated non-inferiority to traditional latanoprost solutions and improved outcomes for patients with Ocular Surface Disease (OSD).

Product Types Covered:

  • Latanoprost
  • Bimatoprost
  • Travoprost
  • Tafluprost
  • Other Product Types

Route of Administrations Covered:

  • Topical
  • Oral
  • Injectable

Distribution Channels Covered:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Specialty Pharmacies
  • Online Distribution

Applications Covered:

  • Glaucoma Treatment
  • Lash Growth Enhancement
  • Ocular Hypertension
  • Dry Eye Disease
  • Gastric Protection
  • Other Applications

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Prostaglandin Analogs Market, By Product Type

  • 5.1 Introduction
  • 5.2 Latanoprost
  • 5.3 Bimatoprost
  • 5.4 Travoprost
  • 5.5 Tafluprost
  • 5.6 Other Product Types

6 Global Prostaglandin Analogs Market, By Route of Administration

  • 6.1 Introduction
  • 6.2 Topical
  • 6.3 Oral
  • 6.4 Injectable

7 Global Prostaglandin Analogs Market, By Distribution Channel

  • 7.1 Introduction
  • 7.2 Hospital Pharmacies
  • 7.3 Retail Pharmacies
  • 7.4 Specialty Pharmacies
  • 7.5 Online Distribution

8 Global Prostaglandin Analogs Market, By Application

  • 8.1 Introduction
  • 8.2 Glaucoma Treatment
  • 8.3 Lash Growth Enhancement
  • 8.4 Ocular Hypertension
  • 8.5 Dry Eye Disease
  • 8.6 Gastric Protection
  • 8.7 Other Applications

9 Global Prostaglandin Analogs Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Pfizer Inc.
  • 11.2 Allergan plc
  • 11.3 Novartis AG
  • 11.4 Bayer AG
  • 11.5 GlaxoSmithKline plc
  • 11.6 Merck & Co., Inc.
  • 11.7 Santen Pharmaceutical Co., Ltd.
  • 11.8 Ocular Therapeutix, Inc.
  • 11.9 Aerie Pharmaceuticals, Inc.
  • 11.10 Sun Pharmaceutical Industries Ltd.
  • 11.11 Yonsung Fine Chemicals
  • 11.12 Everlight Chemical
  • 11.13 Piramal Enterprises
  • 11.14 Bio-Techne Corporation
  • 11.15 Mironova Labs
  • 11.16 Chirogate
  • 11.17 Cepia, LLC
  • 11.18 Johnson Matthey

List of Tables

  • Table 1 Global Prostaglandin Analogs Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global Prostaglandin Analogs Market Outlook, By Product Type (2022-2030) ($MN)
  • Table 3 Global Prostaglandin Analogs Market Outlook, By Latanoprost (2022-2030) ($MN)
  • Table 4 Global Prostaglandin Analogs Market Outlook, By Bimatoprost (2022-2030) ($MN)
  • Table 5 Global Prostaglandin Analogs Market Outlook, By Travoprost (2022-2030) ($MN)
  • Table 6 Global Prostaglandin Analogs Market Outlook, By Tafluprost (2022-2030) ($MN)
  • Table 7 Global Prostaglandin Analogs Market Outlook, By Other Product Types (2022-2030) ($MN)
  • Table 8 Global Prostaglandin Analogs Market Outlook, By Route of Administration (2022-2030) ($MN)
  • Table 9 Global Prostaglandin Analogs Market Outlook, By Topical (2022-2030) ($MN)
  • Table 10 Global Prostaglandin Analogs Market Outlook, By Oral (2022-2030) ($MN)
  • Table 11 Global Prostaglandin Analogs Market Outlook, By Injectable (2022-2030) ($MN)
  • Table 12 Global Prostaglandin Analogs Market Outlook, By Distribution Channel (2022-2030) ($MN)
  • Table 13 Global Prostaglandin Analogs Market Outlook, By Hospital Pharmacies (2022-2030) ($MN)
  • Table 14 Global Prostaglandin Analogs Market Outlook, By Retail Pharmacies (2022-2030) ($MN)
  • Table 15 Global Prostaglandin Analogs Market Outlook, By Specialty Pharmacies (2022-2030) ($MN)
  • Table 16 Global Prostaglandin Analogs Market Outlook, By Online Distribution (2022-2030) ($MN)
  • Table 17 Global Prostaglandin Analogs Market Outlook, By Application (2022-2030) ($MN)
  • Table 18 Global Prostaglandin Analogs Market Outlook, By Glaucoma Treatment (2022-2030) ($MN)
  • Table 19 Global Prostaglandin Analogs Market Outlook, By Lash Growth Enhancement (2022-2030) ($MN)
  • Table 20 Global Prostaglandin Analogs Market Outlook, By Ocular Hypertension (2022-2030) ($MN)
  • Table 21 Global Prostaglandin Analogs Market Outlook, By Dry Eye Disease (2022-2030) ($MN)
  • Table 22 Global Prostaglandin Analogs Market Outlook, By Gastric Protection (2022-2030) ($MN)
  • Table 23 Global Prostaglandin Analogs Market Outlook, By Other Applications (2022-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.